Professor Kumlesh Dev
Professor, Physiology
Professor, Trinity Inst. of Neurosciences (TCIN)
Publications and Further Research Outputs
Peer-Reviewed Publications
Papakyriakopoulou P, Valsami G, Dev KK., The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease., Molecular Neurobiology, Online ahead print, 2024
Béchet S, Dev KK., The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice., Biomedicines, 12, 2024, p594-
Sharma K, Dev KK., The Effects of Antipsychotics in Experimental Models of Krabbe Disease., Biomedicines, 28, 2023, p1313-
Mekhaeil M, Conroy MJ, Dev KK., Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation., J Neuroimmune Pharmacol., 18, 2023, p592 - 609
Moran J, Mylod E, Kane LE, Marion C, Keenan E, Mekhaeil M, Lysaght J, Dev KK, O'Sullivan J, Conroy MJ., Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses., Pharmaceutics, 20, 2023, p360-
Mekhaeil M, Conroy MJ, Dev KK., Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy., Neurotherapeutics, 20, 2023, p1347 - 1368
Fagan SG, Bechet S, Dev KK., Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease, Mol Neurobiol, 59, 2022, p1882 - 1895
Mekhaeil M, Dev KK, Conroy MJ., Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases, Cancers, 29, 2022, p687-
Velasco-Estevez M, Koch N, Klejbor I, Laurent S, Dev KK, Szutowicz A, Sailer AW, Rutkowska A. , EBI2 Is Temporarily Upregulated in MO3.13 Oligodendrocytes during Maturation and Regulates Remyelination in the Organotypic Cerebellar Slice Model. , Int J Mol Sci. , 22, 2021, p4342-
Velasco-Estevez, M. and Koch, N. and Klejbor, I. and Laurent, S. and Dev, K.K. and Szutowicz, A. and Sailer, A.W. and Rutkowska, A., Ebi2 is temporarily upregulated in mo3.13 oligodendrocytes during maturation and regulates remyelination in the organotypic cerebellar slice model, International Journal of Molecular Sciences, 22, (9), 2021
Mampay M, Velasco-Estevez M, Rolle SO, Chaney AM, Boutin H, Dev KK, Moeendarbary E, Sheridan GK. , Spatiotemporal immunolocalisation of REST in the brain of healthy ageing and Alzheimer's disease rats., FEBS Open Bio, 11, 2021, p146 - 163
Clementino A, Velasco-Estevez M, Buttini F, Sonvico F, Dev KK. , Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo., Neurotherapeutics, Online ahead print, 2021
Velasco-Estevez M, Rolle SO, Mampay M, Dev KK, Sheridan GK., Piezo1 regulates calcium oscillations and cytokine release from astrocytes., Glia, 68, 2020, p145 - 160
Béchet S, O'Sullivan SA, Yssel J, Fagan SG, Dev KK., Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease., Journal of Neuroscience, 40, 2020, p3104 - 3118
Velasco-Estevez M, Gadalla KKE, Liñan-Barba N, Cobb S, Dev KK, Sheridan GK., Inhibition of Piezo1 attenuates demyelination in the central nervous system., Glia, 68, 2020, p356 - 375
Neyman S, Braunewell K-H, O'Connell KE, Dev KK, Manahan-Vaughan D, Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation, Frontiers in Synaptic Neuroscience, 11, 2019, p13
Dutta, P. and Dargahi, L. and O'Connell, K.E. and Bolia, A. and Ozkan, B. and Sailer, A.W. and Dev, K.K., A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease, Neuroscience Letters, 673, 2018, p12-18
Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK., Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes., Front Aging Neurosci, 2018, p332-
O'Sullivan, S.A. and O'Sullivan, C. and Healy, L.M. and Dev, K.K. and Sheridan, G.K., Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia, Journal of Neurochemistry, 2018
Rutkowska, A. and Shimshek, D.R. and Sailer, A.W. and Dev, K.K., EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes, Neuropharmacology, 133, 2018, p121-128
Rutkowska, A. and Sailer, A.W. and Dev, K.K., EBI2 receptor regulates myelin development and inhibits LPC-induced demyelination, Journal of Neuroinflammation, 14, (1), 2017, p250-
O'Sullivan S, Dev K.K, Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases, Neuropharmacology, 113, 2017, p597 - 607
Misslin, C. and Velasco-Estevez, M. and Albert, M. and Oâ Sullivan, S.A. and Dev, K.K., Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination, PLoS ONE, 12, (11), 2017, e0187217-
O'Sullivan S.A, Velasco-Estevez M, Dev K.K, Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors, GLIA, 2017, p23148-
Dev K.K, Irving A.J, Lipid sensing G protein-coupled receptors in the CNS, Neuropharmacology, 113, 2017, p595 - 596
O'Sullivan, S.A. and Dev, K.K., The chemokine fractalkine (CX3CL1) attenuates H
O'Sullivan S.A, Gasparini F, Mir A.K, Dev K.K, Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes, Journal of Neuroinflammation, 13, (1), 2016, p189-
Madill M, Fitzgerald D, O'Connell K.E, Dev K.K, Shen S, FitzGerald U, In vitro and ex vivo models of multiple sclerosis, Drug Discovery Today, 21, (9), 2016, p1504 - 1511
Rutkowska A, O'Sullivan S.A, Christen I, Zhang J, Sailer A.W, Dev K.K, The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages, Scientific Reports, 6, 2016, p25520 -
O'Sullivan C, Schubart A, Mir A.K, Dev K.K, The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures, Journal of Neuroinflammation, 13, (1), 2016, p31-
Dev K.K, Common receptor signalling in glial & immune cells, Current Drug Targets, 17, (16), 2016, p1828-
O'Sullivan C, Dev K.K, Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling, Journal of Cell Science, 128, (21), 2015, p3878 - 3887
Rutkowska, A. Preuss, I. Gessier, F. Sailer, A.W. Dev, K.K., EBI2 regulates intracellular signaling and migration in human astrocyte, Glia, 63, (2), 2015, p341 - 351
Sheridan, GK, Dev, KK, Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations, SCIENTIFIC REPORTS, 4, 2014, p5051-
Elain, G. Jeanneau, K. Rutkowska, A. Mir, A.K. Dev, K.K., The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes, Glia, 62, (5), 2014, p725 - 735
Dutta, P., O'Connell, K.E., Ozkan, S.B., Sailer, A.W., Dev, K.K., The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell deat, Journal of Neurochemistry, 130, (3), 2014, p360-373
O'Connell, K.E., Frei, P. , Dev, K.K., The premium of a big pharma license deal, Nature Biotechnology, 32, (7), 2014, p617-619
O'Connell, KE, Thakore, J, Dev, KK, Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine, SCHIZOPHRENIA RESEARCH, 156, (1), 2014, p1-8
Muirhead, G. Dev, K.K., The expression of neuronal sorting nexin 8 (SNX8) exacerbates abnormal cholesterol levels, Journal of Molecular Neuroscience, 53, (1), 2014, p125 - 134
Shrestha, R., Millington, O., Brewer, J., Dev, K.K., Bushell, T.J., Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways, Neuropharmacology, 76, (a), 2014, p184-193
O'Connell, K.E. Thakore, J. Dev, K.K., Increased interleukin 23 (IL23) levels in schizophrenia patients treated with depot antipsychotic medication, Cytokine, 73, (1), 2014, p196-198
David O, Mattes H, Joachim N, Dev KK., 'DERIVADOS DE FTALAZINA E ISOQUINOLINA COM ATIVIDADES MODULADORAS DO RECEPTOR DE S1P.', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0810123, 2014
David O, Mattes H, Joachim N, Dev KK., 'BENZAMIDAS UTILIZÁVEIS COMI MODULADORES DO RECEPTOR DE S1P. ', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0811932, 2014
O'Connell, K.E. Mok, T. Sweeney, B. Ryan, A.M. Dev, K.K., The use of cytokine signature patterns: Separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients, Autoimmunity, 47, (8), 2014, p505 - 511
Pritchard, AJ, Mir, AK, Dev, KK, Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures, PLOS ONE, 9, (6), 2014, p0099444-
Frei, P., Dev, K.K., Drug dealers: $20 trillion of in-licensing payments (Editorial), Drug Discovery Today, 18, (21-22), 2014, p1027-1029
Pritchard, A.J., Dev, K.K. , The role of sphingosine 1-phosphate receptors in the treatment of demyelinating diseases (Review), Future Neurology, 8, (5), 2013, p569-581
O'Connell K, Thakore J, Dev KK, Levels of S100B are raised in female patients with schizophrenia., BMC psychiatry, 13, 2013, p146
O'Sullivan, C., Dev, K.K. , The structure and function of the S1P1 receptor (Review), Trends in Pharmacological Sciences, 34, (7), 2013, p401-412
Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, Dev KK, Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes., British journal of pharmacology, 169, (5), 2013, p1114-1129
Doucet MV, Levine H, Dev KK, Harkin A, Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice., Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, (8), 2013, p1575-1584
Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS Complex: New Drugs for Depression?, Pharmacology & Therapeutics, 133, 2012, p218 - 229
Bolia A, Gerek ZN, Keskin O, Banu Ozkan S, Dev KK, The binding affinities of proteins interacting with the PDZ domain of PICK1., Proteins, 80, (5), 2012, p1393-408
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, IN7219/DELNP/2009, 2012
Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS complex: New drugs for depression?, Pharmacology and Therapeutics, 133, (2), 2012, p218-29
Sheridan GK, Dev KK, S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures., Glia, 60, (3), 2012, p382-92
Claus Rieker, Kumlesh K. Dev, Katja Lehnhoff, Samuel Barbieri, Iwona Ksiazek, Sabine Kauffmann, Simone Danner, Heinrich Schell, Cindy Boden, Markus A. Ruegg, Philipp J. Kahle, Herman van der Putten, Derya R. Shimshek, Neuropathology in Mice Expressing Mouse Alpha-Synuclein, PLoS ONE, 6, (9, e24834), 2011
Joachim N, Mattes H, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', CESAR RAMOS DE MIGUEL, MXMX/A/2009/011421, 2010
P. Dutta, D. Deb, L. Dargahi, D. Ivankovic, K.K. Dev, The GPR37/PAEL Receptor - Finding a Way to the Cell Surface., Drug Discovery , 7, 2010, p36 - 39
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, EP2162427, 2010
David O, Joachim N, Mattes H, Dev KK, 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Huang Gesheng Lin Bainan, CN/101687774, 2010
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Novartis AG Corporate Intellectual Property, EP/2148863, 2010
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Huang Gesheng Lin Bainan, CN/101679274, 2010
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Institutes for Biomedical Research Inc, US/2010/0197753, 2010
Mattes H, Joachim N, David O, Dev KK. , 'BICYCLIC S1P RECEPTOR MODULATORS.', Novartis Institutes for Biomedical Research Inc, US2010/0179153, 2010
Mattes H, Joachim N, David O, Dev KK. , 'HTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING AVTIVITIES', Novartis AG Corporate Intellectual Property, IN/6695/DELNP/2009, 2010
H. Mattes, K.K. Dev, R. Bouhelal, C. Barske, F. Gasparini, D. Guerini, A.K. Mir, D. Orain, M. Osinde, A. Picard, C. Dubois, E. Tasdelen, S. Haessig. , Design and synthesis of selective and potent orally active S1P5 agonists., Chem Med Chem , 5, 2010, p1693 - 1696
Dev KK, Mattes H, Joachim N, David O., 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Davies Collison Cave Pty Ltd, AU/2008/252943, 2009
Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R. , 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES.', Novartis Pharma AG Patent Department. , EP2032599, 2009
S. Chatterjee, J.D. Szustakowski, N.R. Nanguneri, C. Mickanin, M.A. Labow, A. Nohturfft, K.K. Dev* and R. Sivasankaran. , Identification of Novel Genes and Pathways Regulating SREBP Transcriptional Activity. , PLoS ONE , 4, 2009, p5197-
Dev KK, Mattes H, Joachim N, David O. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Davies Collison Cave Pty Ltd, AU/2008/240679, 2009
K.K. Dev, F. Mullershausen, H. Mattes, R. Kuhn, G. Bilbe, D. Hoyer, A. Mir, Brain S1P receptors: implication for fingolimod in the treatment of multiple sclerosis., Pharmacology & Therapeutics , 117, 2008, p77 - 93
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH S1P RECEPTOR MODULATING ACTIVITIES', Novartis AG Corporate Intellectual Property, CA/2684965, 2008
Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, Reed SI, SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis., Genes & development, 22, (2), 2008, p252-64
Senechal Y, Kelly PH, Dev KK, Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning., Behavioural brain research, 186, (1), 2008, p126-32
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, CA/2686953, 2008
Senechal Y, Prut L, Kelly PH, Staufenbiel M, Natt F, Hoyer D, Wiessner C, Dev KK, Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA., Brain research, 1243, 2008, p124-33
Osinde M, Clavaguera F, May-Nass R, Tolnay M, Dev KK, Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation., Neuropathology and applied neurobiology, 34, (5), 2008, p523-31
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, WO/2008/142073, 2008
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES. ', Novartis Pharma AG Patent Department, WO/2008/129029, 2008
Y. Senechal, P.H. Kelly, J.F. Cryan, F. Natt, and K.K Dev., Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. , J. Neurochemistry , 102, 2007, p1928 - 1940
Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R, 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES', Novartis AG Corporate Intellectual Property, WO/2007/141346, 2007
M. Osinde, F. Mullershausen and K.K. Dev. , Phosphorylated FTY720 stimulates ERK phosphorylation in Astrocytes via S1P receptors. Neuropharmacology, 52, 2007, p1210 - 1218
J.F. Cryan and K.K. Dev, The Glutamatergic System as a Potential Therapeutic Target for the Treatment of Anxiety Disorders, PUBLISHED BOOK Handbook of Anxiety and Fear, Elsevier, Academic Press , 17, 2007, p269 - 301
F. Mullershausen, L.M. Craveiro, Y. Shin, M. Cortes-Cros, F. Bassilana, M. Osinde, W.L. Wishart, D. Guerini, M. Thallmair, M.E. Schwab, R. Sivasankaran, K. Seuwen and K.K. Dev. , Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors., J. Neurochemistry , 102, 2007, p1151 - 1161
K.K. Dev, PDZ domain protein-protein interactions: a case study with PICK1, Current Topics in Medicinal Chemistry , 7, 2007, p3 - 20
K.K. Dev, Using RNAi in the Clinic, Investigational Drugs Journal , 9, 2006, p279 - 282
Y. Senechal, Y. Larmet and K.K. Dev, Unraveling in vivo functions of Amyloid Precursor Protein: insights from knockout and knockdown studies, Neurodegenerative Diseases , 3, 2006, p134 - 147
K.K. Dev, S. Chatterjee, M. Osinde, D. Stauffer, H. Morgan, M. Kobialko, U. Dengler, H. Rueeger, B. Martoglio and G. Rovelli, Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals, Eur. J. Pharmacology , 540, 2006, p10 - 17
D. Hoyer and K. K. Dev, RNA interference as a therapeutic strategy for treating CNS disorders, Drug Discovery Today Therapeutic Strategies, 3, 2006, p451 - 456
K.K. Dev and J.M. Henley, The Schizophrenic Faces of PICK1, Trends Pharmacol Sci , 27, 2006, p574 - 579
C. Mahé, E. Loetscher, K.K. Dev, I. Bobirnac, U. Otten and P. Schoeffter., Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells, Neuropharmacology, 49, 2005, p40 - 47
K.L. Madsen, T. Beuming, M.Y. Niv, C-W. Chang, K.K. Dev, H. Weinstein and U. Gether, Delineating the complex PDZ domain binding specificity of PICK1, J. Biol Chem , 280, 2005, p20539 - 20548
K.K. Dev, Making protein interactions druggable: targeting PDZ domains, Nature Reviews Drug Discovery , 3, 2004, p1047 - 1056
C. Mahé, M. Bernhard, I. Bobirnac, C. Keser, E. Loetscher, D. Feuerbach, K.K. Dev and P. Schoeffter, Functional expression of serotonin 5-HT7 receptor in human glioblastoma cell lines, Br. J. Pharmacolology, 143, 2004, p404 - 410
E. Friedmann, M.K. Lemberg, A. Weihofen, K.K. Dev, U. Dengler, G. Rovelli and B. Martoglio, Consensus analysis of Signal Peptide Peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared to Presenilins, J. Biol Chem , 279, 2004, p50790 - 50798
K.K. Dev, S. Nakanishi and J.M. Henley, The PDZ domain of PICK1 differentially accepts Protein Kinase C-á and GluR2 as interacting ligands, J. Biol Chem , 279, 2004, p41393 - 41397
A. Terashima, L. Cotton, K.K. Dev, G. Meyer, S. Zaman, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, Regulation of synaptic strength & AMPA receptor subunit composition by PICK1, J. Neuroscience , 24, 2004, p5381 - 5390
N. Finney, F. Walther, P-Y. Mantel, D. Stauffer, G. Rovelli and K.K. Dev., The cellular protein level of Parkin is regulated by its ubiquitin-like domain, J. Biol Chem, 278, 2003, p16054 - 16058
H. Hirbec, J.C. Francis, S.E. Lauri, S.P. Braithwaite, F. Coussen, C. Mulle, K.K. Dev, V. Couthino, G. Meyer, J.T.R. Isaac, G.L. Collingridge and J.M. Henley, Rapid and differential regulation of AMPA and kainite receptors at hippocampal mossy fibre synapses by PICK1 and GRIP, Neuron , 37, 2003, p625 - 638
K.K. Dev, K. Hofele, S. Barbieri, V. Buchman and H. van der Putten. , Part II: á-Synuclein and its molecular pathophysiological role in neurodegenerative disease, Neuropharmacology, 45, 2003, p14 - 44
K. Cho, J. Francis, H. Hirbec, K. Dev, M. Brown, J. Henley, and Z. I. Bashir, Regulation of kainate receptors by protein kinase C and metabotropic glutamate receptors, J. Physiology , 548, 2003, p723 - 730
K.K. Dev, H. van der Putten, B. Sommer and G. Rovelli, Part I: Parkin-associated proteins and Parkinson's Disease, Neuropharmacology, 45, 2003, p1 - 13
H. Hirbec, O. Perestenko, A. Nishimune, G. Meyer, S. Nakanishi, J.M. Henley, and K.K. Dev, The PDZ Proteins PICK1, GRIP and Syntenin bind multiple glutamate receptor subtypes, J. Biol Chem , 277, 2002, p15221 - 15224
E. Vernon, G. Meyer, L. Pickard, K. Dev, E. Molnar, G.L. Collingridge and J.M. Henley, GABAB receptors couple directly to the transcription factor ATF4, Molecular Cell Neuroscience , 17, 2001, p637 - 645
K.K. Dev, S. Nakanishi and J. M. Henley, Regulation of mGlu7 receptors by proteins that interact with the intracellular C-terminus, Trends Pharmacol Sci , 22, 2001, p355 - 361
M.I. Daw, R. Chittajallu, Z.A. Bortolotto, K.K. Dev, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, PDZ Proteins interacting with c-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses, Neuron , 28, 2000, p873 - 886
K.K. Dev, Y. Nakajima, J. Kitano, S. P. Braithwaite, J. M. Henley and S. Nakanishi, PICK1 interacts with and regulates PKC phosphorylation of mGluR7, J. Neuroscience , 20, 2000, p7252 - 7257
M.J. Keir, M.J. Barakat, K.K. Dev, H. Bittiger, B. Bettler and J.M. Henley, Characterisation of GABAB receptor from rat cerebellum using novel antagonist [3H]CGP 62349, Molecular Brain Research , 71, 1999, p279 - 289
K.K. Dev, A. Nishimune, J.M. Henley and S. Nakanishi, The protein kinase Cá binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits, Neuropharmacology, 38, 1999, p635 - 644
K.K. Dev, T. Honoré and J.M. Henley, Different effects of Phospholipase A2 on agonist binding to hippocampal, cortical and recombinant homomeric AMPA receptors, Neuroscience Letters , 246, 1998, p25 - 28
K.K. Dev and J.M. Henley, The Regulation of AMPA receptor binding sites, Molecular Neurobiology , 17, 1998, p33 - 58
K.K. Dev, C. Foged, H. Andersen, T. Honoré and J.M. Henley, High affinity binding sites for [125I]-labelled pancreatic secretory phospholipase A2 in rat brain, Molecular Brain Research , 49, 1997, p120 - 126
R. Chittajallu, M. Vignes, K.K. Dev, J.M. Barnes, G.L. Collingridge and J.M. Henley, Regulation of glutamate release by presynaptic kainate receptors in the hippocampus, Nature, 379, 1996, p78 - 81
K.K. Dev, V. Petersen, T. Honoré and J.M. Henley, Pharmacology and regional distribution of [3H] 6-nitro-7-sulphamoylbenzo(F)quinoxaline-2-3 dione ([3H]NBQX) binding to rat brain, J. Neurochemistry , 67, 1996, p2609 - 2612
K.K. Dev, P.J. Roberts, and J.M. Henley, Characterisation of the interaction between guanyl nucleotides and AMPA receptors in rat brain, Neuropharmacology, 35, 1996, p1583 - 1593
K.K. Dev, T. Honoré and J.M. Henley, Phospholipase A2 down-regulates the affinity of [3H]AMPA binding to rat cortical membranes, J. Neurochemistry , 65, 1995, p184 - 191
Barnes JM, Dev KK and Henley JM, Cyclothiazide unmasks AMPA-evoked stimulation of [3H]-L-glutamate release from rat hippocampal synaptosomes, Br. J. Pharmacology , 113, 1994, p339 - 341
Dev KK and Morris BJ, Modulation of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites by nitric oxide, Journal of Neurochemistry , 63, 1994, p946 - 952
Non-Peer-Reviewed Publications
Dev KK, 6th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 186, 2017, p281 - 298
Dev KK, 5th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 185, 2016, p169 - 185
Dev KK, Neurology, Professor Kumlesh Dev sets out Ireland's position on brain disease. Irish Independent (Supplement), 2015, -
Dev KK, 4th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 184, 2015, p1 - 18
Dev KK, 3rd Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci. , 183, 2014, p71 - 85
Dev KK, 2nd Annual Meeting. Block MS Ireland. Neuroprotection: At the cellular, in vivo and clinical level., Irish J Med. Sci., 182, 2013, p1 - 13